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Inter-observer variabilityBackground and purpose: Boosting the dose to the largest (dominant) lesion in radiotherapy of prostate
cancer may improve treatment outcome. The success of this approach relies on the detection and delin-
eation of tumors. The agreement among teams of radiation oncologists and radiologists delineating
lesions on multiparametric magnetic resonance imaging (mp-MRI) was assessed by measuring the dis-
tances between observer contours. The accuracy of detection and delineation was determined using
whole-mount histopathology specimens as reference.
Material and methods: Six observer teams delineated tumors on mp-MRI of 20 prostate cancer patients
who underwent a prostatectomy. To assess the inter-observer agreement, the inter-observer standard
deviation (SD) of the contours was calculated for tumor sites which were identiﬁed by all teams.
Results: Eighteen of 89 lesions were identiﬁed by all teams, all were dominant lesions. The median his-
tological volume of these was 2.4 cm3. The median inter-observer SD of the delineations was 0.23 cm.
Sixty-six of 69 satellites were missed by all teams.
Conclusion: Since all teams identify most dominant lesions, dose escalation to the dominant lesion is fea-
sible. Sufﬁcient dose to the whole prostate may need to be maintained to prevent under treatment of
smaller lesions and undetected parts of larger lesions.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 115 (2015) 186–190.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Boosting the radiation dose to the visible cancer inside the pros-
tate may improve treatment outcome. This theory is motivated by
the observation that prostate cancer often recurs at the site of the
dominant lesion [1,2] and by observations that escalating the radi-
ation dose improves treatment outcome [3]. A boost to the largest
lesion in the prostate (the dominant lesion), in addition to a stan-
dard dose to the whole organ may achieve adequate dose escala-
tion without increasing toxicity [4,5]. This hypothesis is currently
tested in a phase III clinical trial, the FLAME trial [6]. Boost volumes
can be deﬁned on multiparametric magnetic resonance imaging
(mp-MRI).
Mp-MRI, consisting of a combination of T2-weighted (T2w), dif-
fusion-weighted (DWI) and dynamic contrast enhanced (DCE)images, has a high diagnostic accuracy for detection of prostate
cancer [7,8]. By dividing the gland into regions and scoring tumor
presence per region, speciﬁcities and sensitivities for tumor detec-
tion in the range of 0.53–0.81 and 0.80–0.96 are feasible [9].
Sensitivity using all three modalities together is higher than for
the separate modalities [10].
The inter-observer agreement of tumor detection can be quan-
tiﬁed using a kappa statistic. The number of volume elements
(regions of the prostate or voxels in the images) for which the
observers agree is expressed as a value ranging from zero (no
agreement) to one (perfect agreement). Studies of region-based
tumor detection on mp-MRI have reported kappa values ranging
from 0.40 to 0.63 [11,12]. Rischke et al. [13] performed a kappa
analysis on a voxel-by-voxel basis in ﬁve patients. They compared
tumor delineations of ﬁve observers with delineations by a refer-
ence observer, resulting in an agreement of 0.51 ± 0.15
(mean ± standard deviation; range 0.22–0.73) for a combination
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with DCE images. Delineation on a combination of all three MR
sequences was not studied by these authors. Anwar et al. com-
pared delineations by two observers on T2w imaging and MR spec-
troscopy with delineations on histology and found these to differ
by a median distance of 1.4 mm [14].
In this study, we determine the inter observer agreement and
geometrical distances between the contours of the observers. The
latter is the measure closest to the delineation practice in radio-
therapy. Six teams from three different centers were recruited,
each team consisting of a radiation oncologist and a radiologist,
which delineated prostate tumors on mp-MRI. By comparing the
results with histology, we assessed to what extent tumors were
correctly identiﬁed and what the agreement was between the
observer and pathology contours.Methods
Dataset
Twenty patients with biopsy proven prostate cancer were
selected who consulted the Department of Radiation Oncology of
the University Hospitals Leuven. The patients were prospectively
included in an earlier study [10,15]. Between February 2008 and
February 2011 they underwent an mp-MRI exam before prostate-
ctomy. The patients were selected such that the majority had T2c
or T3a prostate cancer based on analysis of the prostatectomy
specimens. Apart from tumor stage, the selection was random.
Written informed consent was obtained from all patients.
The mp-MRI scan consisted of T2-weighted (T2w), diffusion
weighted (DWI), and dynamic contrast-enhanced (DCE) scans.
These were acquired on 1.5T MR scanner (SonataVision,
SymphonyVision or Aera, Siemens Erlangen, Germany) using a
combination of a six-channel phased-array body coil and a spine
coil. Because the patients were selected retrospectively, the scan-
ning parameters varied (see Supplementary material). Orthogonal
transversal, coronal and sagittal T2w scans were acquired. ADC
maps were calculated from the DWI scan by the scanner software.
For the DCE scans, the contrast agent (Dotarem, Guerbet, France,
15 ml) was injected at the fourth dynamic scan with a rate of
2 ml/s, followed by a 20 ml saline ﬂush. The signal intensities were
ﬁrst converted to gadolinium concentration values [16] using ref-
erence T1 values [17]. The extended Tofts model was ﬁtted to
the concentration time curves for estimation of the volume
transfer constant (Ktrans) using the method by Murase [18] with a
population-based arterial input function.
Six teams of delineators were recruited from three hospitals
(two teams per hospital). Each team consisted of a radiation oncol-
ogist and a radiologist. Using the mp-MRI, they delineated the vis-
ible tumors on the transversal T2 (T2t) scan. To assure that the
study results are representative for a realistic clinical situation,
the teams used the delineation system of their own hospital. The
teams were provided with biopsy information, TRUS ﬁndings and
written radiology reports. The ﬁnal delineations were approved
by both members of the team.Pathology
Whole-mount histological slices were cut from the prostatec-
tomy specimens perpendicular to the urethra at 3–4 mm intervals
[10,15]. From these, Hematoxylin-eosin (H&E) stained whole-
mount pathology slideswere obtained onwhich a single pathologist
delineated the tumors. The H&E slides were registered to the T2t
image to allowassessment of tumordetection accuracy of the obser-
vers. First, each pathology slide was assigned to a T2t slice based on
the relative order of the H&E slides, the location of apex and base,size of the subsequent slices in MRI and pathology and the distance
between the slides (3 or 3.3 mm in T2t, 3–4 mm in histology). For
some T2t slices no H&E slice was present due to the difference in
slice distance. The location of the pathology slides does not neces-
sarily coincidewith the location of theMRI slices. Therefore the true
location of an H&E slice in the T2t scan can be somewhere between
two slices. The T2t slice distance is 3.3 mm for most patients;
assuming that the best matching T2w slice is selected, the average
error is 0 mm, ranging from 1.65 to +1.65 mm. The average abso-
lute error in the slice direction is then 0.8 mm.
Subsequently, each slice was registered by means of a deform-
able point-based method (Coherent Point Drift) using landmark
points which were visible on both images. These were mostly
based on the prostate boundary and occasionally other features,
such as the ends of the peripheral zone and transitions between
prostate and seminal vesicles. We estimated the registration error
by selecting one landmark not used for registration per pathology
slice and measuring the distance between this point on T2t MRI
and registered pathology. The average error we found was
2.1 mm; the largest error was 5 mm. We could not assess the error
resulting from possible differences in orientation of the pathology
slices and the imaging.
The pathologist delineated the tumor locations on the H&E
slices prior to registration. These delineations were digitized after
image registration. The contours of seven dominant lesions and
one satellite were interpolated for slices where no matching H&E
slice was present while a tumor was found at the same site in both
the previous and next slice.Analysis
All contour analyses were done by one author using each
patient’s T2t scan grid as unit of analysis. The contours of the same
site by different teams were grouped manually based on overlap.
Depending on whether or not a corresponding pathology contour
was found in the histology, the contour groups were counted as
true positives, false positives and false negatives. Delineations
made on MRI slices without matching histology were categorized
as unconﬁrmed.
The prostate voxels were divided in healthy/tumor based on
pathology and in true/false positive/negative based on pathology
and consensus detections by all teams. The median and quartile
of the voxel values of these categories were calculated for all scans.
For this, all images were ﬁrst normalized to their median.
The volumes of the observer delineations were estimated by
counting the number of T2t voxels in the contours and multiplying
this by the voxel volume. The same was done for the digitized
pathologist’s contours. Differences between teams in delineated
volumes were analyzed using the Friedman test in Matlab (version
8.1, Statistics Toolbox 8.2, Natick, Massachusetts: The MathWorks
Inc., 2013), with the observer teams as factor and patients as ‘‘nui-
sance factor’’.
The inter-observer delineation variation of the tumor sites
which were delineated by all teams was assessed relative to a ref-
erence contour. The measure of interest was the standard deviation
of the contour distances. The exact shape of the reference contour
is not important for this, as long as it is smooth and similar in
shape to the contours to be tested. The pathologist’s contours
had irregular shapes in some cases, making them unsuitable as a
reference. Instead, the median of the observer contours was used,
which was obtained by converting each contour to a mask, adding
the six masks, smoothing the result and contouring the 50% level.
The perpendicular distances of all points of the reference contour
to each observer contour were then calculated and pooled [19].
The standard deviation (SD) of this pool was then calculated to
obtain the inter-observer variability for one tumor site.
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assessed the agreement at the voxel level using kappa indices.
When applied to detection in voxels, this index is identical to the
DICE index. For tumors detected by all six teams, all 15 pair-wise
kappa statistics were calculated. The agreement between pathol-
ogy contours and the team delineations was also quantiﬁed using
the kappa statistic; all observer contours were compared to the
corresponding tumor found on pathology.
Results
Table 1 shows the characteristics of the 20 patients included in
the present study. Histological analysis of the whole mount prosta-
tectomy specimens revealed tumor stages ranging from T2b to T3b
and Gleason scores from 7 to 9. A total of 89 tumors were found in
the histology, 22 were larger than 0.4 cm3. The scan values of the
healthy prostate tissue and tumor are presented in Table 2.
An example of delineations by the six teams at the site of a
dominant lesion is shown in Fig. 1. In this example, all teams indi-
cated the same tumor location but the delineated tumor bound-
aries differed. Both over- and underestimations of tumor
boundaries were made by the teams.
Forty sites were identiﬁed by one or more teams, of which 22
were true positives. Nineteen sites were detected by all teams,
18 of which were true positives; the 19th was a satellite at a site
for which no matching histopathology was available. All 18 trueTable 1
Patient data. The information in the ﬁrst four columns was available to the observers; the i
biopsy information of left (L) and right (R) hemispheres is coded as: number of positive b
information about the total number of biopsies was available.
Patient Clinical information (available to observers) Pat
Gleason score
(biopsy)
T stage TRUS (fMRI) Number of positive biopsy
cores (total)
Gle
1 3 + 3 T2c-T3b L2(5)/R1(5) 4 +
2 3 + 4 T2a (T2c) L1(5)/R2(5) 4 +
3 3 + 4 T3a (T2a) 3(3) 3 +
4 4 + 4 T2b-T3a (T2b) L2(4)/R2(4) 4 +
5 4 + 3 T3a (T3a) L1(2)/R3(4) 4 +
6 4 + 3 T3a (T3a) L1(4)/R0(4) 4 +
7 5 + 4 T2c (T2c) L2(5)/R4(5) 4 +
8 3 + 4 + 5 T2a (T3a) L1(3)/R1(3) 4 +
9 3 + 4 T3b (T3b) 2(2) 4 +
10 4 + 3 T2–T3a (T3a) L5(5)/R(5) 4 +
11 4 + 3 T2b–T3a (T3b) L3(4)/R0(4) 4 +
12 4 + 4 T3b (T3a) L0(3)/R0(3) 5 +
13 4 + 3 T3a (T3a) 2(6) 4 +
14 4 + 4 T3a (T3b–T4) L1(5)/R3(5) 4 +
15 4 + 4 (T3a) L0(5)/R5(5) 4 +
16 4 + 3 T3b (T3b) L2(5)/R5(5) 4 +
17 4 + 4 T2a (T2c) L3(5)/R0(5) 4 +
18 4 + 5 T2a (T2c) L0(5)/R1(5) 4 +
19 4 + 3 T3a (T3a) L5(5)/R2(5) 3 +
20 3 + 4 T3b (T2a) 3* 4 +
* For this patient the total number of biopsies was not reported.
Table 2
Imaging values of prostate tumor and healthy tissue together with true/false positives and
voxels (i.e. all or no teams detected the voxels) were included. The imaging data were norm
the prostate. The values are shown as median and quartile values of all normalized voxel
Pathology C
Positive Negative T
T2 normalized Median 0.95 1.01 0
Quartiles [0.78–1.16] [0.78–1.29] [
Ktrans normalized Median 1.41 0.96 1
Quartiles [0.94–2.12] [0.59–1.47] [
ADC normalized Median 0.86 1.01 0
Quartiles [0.72–1.02] [0.89–1.13] [positives were dominant lesions. Of the 21 sites delineated by
some but not all teams, 4 were true and 17 were false positives.
The largest true positive was the dominant lesion of patient 18.
Table 2 shows the scan values for the consensus detections.
The dominant lesion of patient 1 was missed by all teams. It
was located in the ventral part of the central zone; the biopsy
report, however, indicated one positive biopsy in the right half
of the prostate, where no tumor was found in histology, and
two positives biopsies in the left half, where pathology revealed
only small satellites. Sixty-six of 69 satellites were missed by
all teams.
The 18 correctly detected dominant lesions had a median
histological volume of 2.4 cm3 (range 0.9–10.5 cm3). The median
volume of the other 71 lesions was 0.02 cm3. Four of these were
larger than 0.4 cm3. The missed dominant lesion of patient 1 had
a volume of 1.9 cm3. The dominant lesion of patient 18 was also
missed, but had a volume of only 0.45 cm3. Two satellite lesions
had volumes of 0.9 cm3and 0.79 cm3 respectively; the other lesions
had a smaller volume. The volumes delineated by each of the six
teams are shown in Fig. 2; the median delineated volumes differ
signiﬁcantly between teams (Friedman’s ANOVA: X2(5) = 43.02,
p < 0.001).
Fig. 3 presents the inter-observer SDs of the 18 commonly
detected tumors. The median of these 18 SDs was 0.23 cm (range
0.13–0.62 cm); no dependence of tumor volume is visible. The
inter-observer SD for the dominant lesion of patient 17 was muchnformation in the other columns was derived from the prostatectomy specimens. The
iopsies (total number of biopsies). In patients where the L/R labels are missing, only
hology information (not available to observers)
ason score T stage Volume of dominant
lesion [cm3]
Notes
4 T2c 1.88 Mostly located in central gland
3 T2c 1.34
4 T3a 1.72 Satellite of 0.71 cm3
3 T3a 0.94
3 T2c 1.54
3 T3a 2.23
3 T3a 2.43 Satellite of 1.00 cm3
4 T2c 1.22
4 T3b 8.96
3 T3a 8.85
3 T3a 3.26
4 T3a 5.22
3 T3a 3.84
4 T3b 1.93
4 T3a 6.67
4 T3b 10.52
4 T2c 2.32
5 T2b 0.45
4 T2c 3.16
4 T2c 1.87
negatives of the observer detections inside the prostate. For the latter, only consensus
alized per patient and per scan by dividing the data through the median value inside
s of all patients.
onsensus detections
rue positive False positive True negative False negative
.85 0.87 1.02 1.09
0.72–0.99] [0.73–1.01] [0.78–1.32] [0.87–1.36]
.97 1.92 0.92 0.99
1.41–2.64] [1.39–2.67] [0.56–1.40] [0.69–1.43]
.73 0.76 1.02 1.00
0.64–0.84] [0.67–0.90] [0.91–1.34] [0.86–1.13]
Fig. 1. (A–C) Example of delineations by the six teams on T2w, Ktrans and ADC images. Panel D shows the corresponding H&E stained slice with the pathologist’s contours in
blue dots. Panel E shows the H&E slice registered to the T2w scan. Panel F shows delineations overlaid on the prostate in gray and tumor presence as determined by the
pathologist in white.
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Fig. 2. Delineated volumes of the 18 tumors delineated by all teams and the
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Fig. 3. Inter-observer standard deviations as function of pathological tumor
volume. Patient 17 is discussed in the Results section.
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locking without being centered at the same location.
The kappa indices for the agreement between the delineations
of the teams were 0.61 ± 0.19 (mean ± SD), ranging from 0 to
0.87. The kappa indices for the agreement between delineations
of the teams and the pathologist were 0.45 ± 0.16, ranging from
0.08 to 0.74. This indicates that the agreement in delineation
between teams was higher than the agreement between the teams
and the pathologist’s delineations on histology.Discussion
We investigated the accuracy with which multiple teams detect
and delineate prostate tumors on mp-MRI. The teams detected 18
of 22 tumors larger than 0.4 cm3, all of which were dominant
lesions. In two patients no dominant lesion was delineated by con-
sensus. In one, the largest tumor identiﬁed by the pathologist wastoo small to be visible on MR. In the other case, the tumor delin-
eated by the pathologist was sparse, meaning that it mostly con-
sists of normal tissue interspersed with a large number of small
lesions [20]. Since the central gland is heterogeneous by itself, this
volume was not visible on MRI.
The teams differed in delineation of the tumor boundaries.
For the delineated dominant lesions, the mean kappa value of
0.60 in our data is close to the value found by Rischke et al.
[13]. The kappa statistic for agreement between observers and
pathology was lower than the kappa between observers. This
indicates that the observers to some extent delineate the same
volumes and that they miss the same parts of the tumors. The
missed parts of the tumor may be the consequence of these
parts not being visible on MRI due to low Gleason score or spar-
sity of the tumor.
The difference in delineated volumes between teams suggests
that some teams make more conservative estimates than others.
This may be due to differences in interpretation of the images
and to the importance that is attached to each of the MRI modali-
ties. There is currently no consensus on optimal use of each of the
series. Additional differences may occur depending on latent
knowledge about treatment options and the wish to ensure that
190 Variability of prostate tumor delineationthe boost covers the tumor and therefore preferring wider tumor
delineations in case of doubt.
The beneﬁt of boosting may be limited by the accuracy of tumor
delineation. This beneﬁt will increase if the tumor delineations
include more tumor tissue, which may be achieved by applying a
margin to the delineated tumors. This expansion may be relatively
small compared to margins for the whole gland since the dose
fall-off from boost area to uniform dose will be shallow [21]. An
alternative would be to increase the accuracy of delineation, for
instance by increasing the visibility of tumors on MRI by improving
scanning sequences or equipment or by training the observers to
increase the consensus of delineation on mp-MRI. Additionally,
consulting statistical model predictions on tumor presence
[22,23] could provide helpful cues when delineating prostate
tumors.
None of the seventeen false positives were delineated by all
teams, suggesting that the information in the mp-MRI for these
sites is ambiguous. Studying the properties of these areas of ambi-
guity may result in methods to provide single observers with cues
about this uncertainty.
No tumors other than the dominant lesion were identiﬁed by all
our teams, leaving 69 satellites undetected, most of which were
smaller than 0.4 cm3. The clinical relevance of satellite tumors in
the prostate is currently a matter of debate. It has been suggested
that these satellites do not require treatment since they show less
hallmarks of cancer than the dominant lesions [24]. However,
Huang et al. recently found small satellites to exhibit high
Gleason patterns in 11% of their patients, which suggests that small
foci do require treatment some cases [25]. For this reason, current
boost trials maintain the dose to the organ outside the boost area
at the regular clinical level.
Since patients were selected retrospectively, no special mea-
sures could be taken to optimize registration accuracy of histology
on MRI. Some of the differences between the pathology and obser-
ver contours may be due to limited registration accuracy and the
observer-to-pathology kappa statistic may therefore be biased
downwards. Additionally, the pathology contours which we used
as the gold standard are themselves due to inter observer variation.
Volume estimates of small lesions which only appear in one slice
are likely to be overestimated. The seminal vesicles and apex are
not included in our histology stacks since they are handled
separately by the pathology department; therefore volumes of
tumors which extend toward the base or apical slice may be
underestimated.
In conclusion, all teams consisting of a radiation oncologist and
a radiologist found 18 of 20 veriﬁable dominant prostate lesions on
mp-MRI. The inter-observer contour standard deviation for these
tumors was 2.3 mm. The observers missed parts of the dominant
lesions and all satellites, two of which were larger than 0.4 cm3.
A sufﬁcient dose outside the boost volume should therefore be
maintained to cover these missed volumes.
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